participation in self management programmes, open access appointments and the value of their hospital appointments when well. Thematic analysis of interviews was undertaken using NVivo 9.0.

Results No patients were enrolled into a self management programme. Only two had heard of self management. Four clear groups of patients perspectives of self management emerged: (1) patients who embraced the concept of self management and questioned why they had not heard of it prior to the interview; (2) patients who dismissed self management and could perceive no advantages to it, would not take “responsibility for their body”; (3) patients who were willing to embark on a programme with the caveat that if they could not manage, they could revert back to the traditional care system; and (4) patients who required more knowledge about their illness and body response before considering self management. All patients were concerned about open—access and a fear of not “getting in” when needed. This led to an unwillingness to accept this yet all but one of the 24 patients stated that, when well, their hospital appointment was often a waste of their time and the healthcare professionals’ time.

Conclusion Integrated care pathways for patients with inflammatory bowel disease should be responsive to their clinical needs, be feasible and acceptable to those delivering and receiving care. When designing new modes of care delivery, consideration must be given to the group of patients that will not, or cannot self manage. Patients also appear to lack confidence in new modes of care delivery. Re-building this confidence is vital to the successful implementation of integrated care pathways where there is an element of self management.

PMO-025 **THREE-YEAR REVIEW OF LOCAL HEPATO-PANCREATOBILIARY (HPB) CANCER SERVICE & ITS IMPACT ON CANCER DETECTION IN A NON-TERTIARY CENTRE IN MERSEY REGION**

doi:10.1136/gutjnl-2012-302514b.25

K Clark,* A Boon, R Faizallah, A Singhal. *HPB, Arrowe Park Hospital, Liverpool, UK*

Introduction Patients with HPB cancer pose complex clinical problems requiring close liaison between primary, secondary & tertiary care. Reconfiguration of cancer services in the Mersey region has led to standardisation of care for HPB cancer patients via referral to Regional Specialist Centres (RSC). However local cancer care remained fragmented and limited by the variable expertise of the respective clinical teams involved. Therefore we developed a local HPB Cancer Service (HPBCS) and hereby report 3-year impact of this service on overall patient care and cancer detection rates outside tertiary referral centres.

Methods The HPBCS was launched on the Wirral in June 2008, the first such service in a large district general hospital (catchment population of 360 000) in the Mersey region. All patients with suspected HPB cancer were referred to the local HPB Team comprising of two HPB consultants and a specialist nurse. Patients are identified via 2-week referrals from primary care, acute admissions, ward referrals and radiology flags—a new concept that year upon year provides a valuable resource to the service. All patients are managed as per the Mersey & Cheshire Cancer Network protocol with discussion at the appropriate RSC MDT meetings. The team meets weekly to discuss all new referrals, MDT outcomes and any sick patients. In addition to the consultant clinics, there is weekly HPB nurse-led outpatient & telephone clinics that provides urgent feedback of tertiary MDT decisions, rapid access for symptom control and ensures continuity of care.

Results There is a sharp increase in the HPB cancer detection and referral rates since establishing the local HPBCS which has sustained over 3-year period as summarised in Abstract PMO-025 table 1.

Abstract PMO-025 Table 1

	Pre HPBCS 2007	Post HPBCS 2009/2010/2011		
Pancreatic lesions				
Pancreatic cancer resectable/ non-resectable	NA	59/24	72/40	64/26
IPMN	NA	45	83	48
Benign pancreatic lesions	NA	47	33	40
Total	51	175	252	178
	Pre HPBCS 2007	Post HPBCS 2009/2010/2011		
Hepato-biliary lesions				
Cancers (HCC/gallbladder/ cholangio)	NA	34/13/9	42/2/8	46/13/11
Benign liver lesions	NA	25	65	51
Indeterminate liver lesions	NA	21	4	18
Total	26	102	121	139

Conclusion Since commencement of local HPBCS, there is sustained increase in number of suspected HPB cancers identified within the trust. These are referred on to the regional MDTs within 2 weeks, leading to timely and uniform care as per regional network guidelines with local ownership of care. Service was formally praised in MCCN peer review in 2010 and awarded Wirral Trust Foundation Award in 2011. There is small but consistent rise in detection of liver lesions which may reflect increasing incidence of chronic liver diseases nationally. Ever increasing pool of surveillance patients & radiology alerts contribute to significant ongoing work load.

Competing interests None declared.

PMO-026 **RE-AUDIT OF ACTION ON POSITIVE *H. PYLORI* (HP) SEROLOGY: SIGNIFICANTLY BETTER ... NOT YET PERFECT**

doi:10.1136/gutjnl-2012-302514b.26

¹M Srinivas,* ²S Yeomans, ²P Morris, ²P Basumani, ²K Bardhan.* ¹Department of Gastroenterology, Global Hospitals & Health City, Chennai, India; ²Department of Gastroenterology, The Rotherham Hospitals NHS Foundation Trust, Rotherham, UK

Introduction We identified a patient with duodenal ulcer re-bleed whose earlier *Hp* seropositive result was overlooked, hence not acted on. This triggered an audit¹ of action taken on hospital-initiated *Hp* seropositive results. It showed inadequate action in 17% due to multiple serology request sources, unclear advice from endoscopists & varied involvement of endoscopy specialist nurses (SpN). As most *Hp* serology tests were initiated at endoscopy, SpN were made the single point of contact to test, review/action results & confirm eradication by Urea Breath Test (UBT) in seropositives. Two actions were taken in November 2010: a copy of all hospital clinician initiated seropositive results to be sent by Microbiology lab to SpN & a code “ESN” created in the lab system for SpN to request & receive serology results directly.

Aim To re-audit management of *Hp* seropositive patients since introducing the above measures.

Methods Retrospective study of all hospital clinician initiated *Hp* seropositive results between January and June 2011 (list from microbiology lab database). Proof of action was got from our Medical Physics UBT database, SpN contact log, Endoscopy reporting software (endoscopist advice on testing & action if positive) and notes review when data not obtainable from these sources.

Results 90 seropositive patients identified; seven excluded from analysis as they died soon after test (cancer in most). *Action on Hp positive results*: 82/83(99%) results acted upon. One with metastatic cancer was tested (contrary to endoscopist advice) & result overlooked by ward team. SpN reviewed 75/82 (92%) patients and